Seattle Genetics Inc /wa (SGEN): Clay B Siegall , President and CEO of Seattle Genetics Inc /wa sold 7,618 shares on May 17, 2016. The Insider selling transaction was reported by the company on May 19, 2016 to the Securities and Exchange Commission. The shares were sold at $35.16 per share for a total value of $267,848.88 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 26, 2016, Clay B Siegall (President and CEO) sold 800 shares at $40.00 per share price.On Feb 17, 2016, John A Orwin (director) purchased 2,000 shares at $28.33 per share price.Also, On Dec 16, 2015, Vaughn B Himes (EVP, Proc Svcs & Tech Ops) sold 40,500 shares at $39.94 per share price.On Nov 13, 2015, Darren S Cline (SVP, Commercial) sold 5,769 shares at $45.68 per share price.
Shares of Seattle Genetics (SGEN) ended Thursday, May 19, 2016 session in red amid volatile trading. The shares closed down -0.11 points or -0.29% at $37.91 with 8,59,290 shares getting traded. Post opening the session at $37.79, the shares hit an intraday low of $37.08 and an intraday high of $38.92 and the price vacillated in this range throughout the day. The company has a market cap of $5,314 M and the number of outstanding shares has been calculated to be 14,01,67,030 shares. The 52-week high of Seattle Genetics is $52.3299 and the 52-week low is $26.02.
Company has been under the radar of several Street Analysts.Seattle Genetics is Initiated by Sun Trust Rbsn Humphrey to Neutral and the brokerage firm has set the Price Target at $34. The Rating was issued on Mar 3, 2016.
Seattle Genetics Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company’s marketed product ADCETRIS or brentuximab vedotin is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent monomethyl auristatin E (MMAE) utilizing its technology. In addition to ADCETRIS the Company’s pipeline includes six clinical-stage ADC programs consisting of SGN-CD33A SGN-CD19A SGN-LIV1A SGN-CD70A ASG-22ME and ASG-15ME and SEA-CD40 which is based on its sugar-engineered antibody (SEA) technology. In addition it has multiple preclinical and research-stage programs that employ its technologies. Its technologies include ADC technology and Seattle Genetics’ sugar-engineered antibody (SEA) technology.